These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20973270)

  • 1. Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary.
    Tsuda H; Ito K; Yaegashi N; Hirasawa A; Sudo T; Kita T; Terai Y; Kigawa J; Sugiyama T; Aoki D
    Int J Gynecol Cancer; 2010 Jul; 20(5):794-7. PubMed ID: 20973270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.
    Tsuda H; Ito YM; Ohashi Y; Wong KK; Hashiguchi Y; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6880-8. PubMed ID: 16203778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs.
    Nishimura S; Tsuda H; Ito K; Jobo T; Yaegashi N; Inoue T; Sudo T; Berkowitz RS; Mok SC
    Hum Pathol; 2007 Jan; 38(1):134-9. PubMed ID: 16996567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can ABCF2 protein expression predict the prognosis of uterine cancer?
    Nishimura S; Tsuda H; Miyagi Y; Hirasawa A; Suzuki A; Kataoka F; Nomura H; Chiyoda T; Banno K; Fujii T; Susumu N; Aoki D
    Br J Cancer; 2008 Nov; 99(10):1651-5. PubMed ID: 19002184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
    Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
    Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
    J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
    Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
    Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Cancer; 1996 Nov; 78(10):2157-63. PubMed ID: 8918409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of ABCF2 expression in breast cancer.
    Ogawa Y; Tsuda H; Hai E; Tsuji N; Yamagata S; Tokunaga S; Nakazawa K; Tamamori Y; Ogawa M; Shimizu S; Inoue T; Nishiguchi Y
    Anticancer Res; 2006; 26(3A):1809-14. PubMed ID: 16827111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
    Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
    Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
    J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
    Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
    Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
    Kita T; Kikuchi Y; Kudoh K; Takano M; Goto T; Hirata J; Tode T; Nagata I
    Oncol Rep; 2000; 7(2):327-31. PubMed ID: 10671681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sugiyama T; Kikuchi Y; Suzuki M; Terakawa N
    Obstet Gynecol; 2002 Aug; 100(2):281-7. PubMed ID: 12151151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
    Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
    Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
    Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
    Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
    Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
    Nishimura S; Tsuda H; Ito K; Takano M; Terai Y; Jobo T; Kigawa J; Sugiyama T; Yaegashi N; Aoki D
    Int J Gynecol Cancer; 2010 Feb; 20(2):220-6. PubMed ID: 20134266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.